AUSTIN, Texas–(BUSINESS WIRE)–IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQNEURSA® (levacetylleucine) for the treatment of ataxia in adult and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. AQNEURSA is the first and only drug approved for the treatment of A-T anywhere in the world. In the United